Overview:We are an international pharmaceutical company governed by a non-profit foundation, with our headquarters in France (Suresnes).
With a strong international presence in 149 countries and a turnover of 4.176 billion euros in 2018, we employ 22.000 people worldwide.
Entirely independent, we reinvest 25% of our turnover (excluding generic drugs) in research and development and use all our profits for development.
Corporate growth is driven by our constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric disease, cancer and diabetes, as well as by our activities in high-quality generic drugs.
Currently, we have 33 drug candidates including 22 new molecular entities at various stages of clinical development. Our priorities are pathologies with high medical needs within our areas of expertise.
To report a suspected adverse event with a Servier drug, please visit www.servier.com